732 related articles for article (PubMed ID: 16952647)
1. Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer.
Zelefsky MJ; Chan H; Hunt M; Yamada Y; Shippy AM; Amols H
J Urol; 2006 Oct; 176(4 Pt 1):1415-9. PubMed ID: 16952647
[TBL] [Abstract][Full Text] [Related]
2. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer.
Zelefsky MJ; Fuks Z; Hunt M; Lee HJ; Lombardi D; Ling CC; Reuter VE; Venkatraman ES; Leibel SA
J Urol; 2001 Sep; 166(3):876-81. PubMed ID: 11490237
[TBL] [Abstract][Full Text] [Related]
3. Hypofractionated intensity-modulated radiotherapy (70 gy at 2.5 Gy per fraction) for localized prostate cancer: long-term outcomes.
Kupelian PA; Thakkar VV; Khuntia D; Reddy CA; Klein EA; Mahadevan A
Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1463-8. PubMed ID: 16169683
[TBL] [Abstract][Full Text] [Related]
4. Improved biochemical disease-free survival of men younger than 60 years with prostate cancer treated with high dose conformal external beam radiotherapy.
Zelefsky MJ; Marion C; Fuks Z; Leibel SA
J Urol; 2003 Nov; 170(5):1828-32. PubMed ID: 14532785
[TBL] [Abstract][Full Text] [Related]
5. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era.
Kupelian P; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A; Kuban D
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):795-9. PubMed ID: 15925452
[TBL] [Abstract][Full Text] [Related]
6. Ultra-high dose (86.4 Gy) IMRT for localized prostate cancer: toxicity and biochemical outcomes.
Cahlon O; Zelefsky MJ; Shippy A; Chan H; Fuks Z; Yamada Y; Hunt M; Greenstein S; Amols H
Int J Radiat Oncol Biol Phys; 2008 Jun; 71(2):330-7. PubMed ID: 18164858
[TBL] [Abstract][Full Text] [Related]
7. High-dose-rate intensity-modulated brachytherapy with external beam radiotherapy for prostate cancer: California endocurietherapy's 10-year results.
Demanes DJ; Rodriguez RR; Schour L; Brandt D; Altieri G
Int J Radiat Oncol Biol Phys; 2005 Apr; 61(5):1306-16. PubMed ID: 15817332
[TBL] [Abstract][Full Text] [Related]
8. Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995.
Kupelian P; Kuban D; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A
Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):415-9. PubMed ID: 15667961
[TBL] [Abstract][Full Text] [Related]
9. Clinical results of combined treatment conformal high-dose-rate iridium-192 brachytherapy and external beam radiotherapy using staging lymphadenectomy for localized prostate cancer.
Hiratsuka J; Jo Y; Yoshida K; Nagase N; Fujisawa M; Imajo Y
Int J Radiat Oncol Biol Phys; 2004 Jul; 59(3):684-90. PubMed ID: 15183471
[TBL] [Abstract][Full Text] [Related]
10. Analysis of toxicity in patients with high risk prostate cancer treated with intensity-modulated pelvic radiation therapy and simultaneous integrated dose escalation to prostate area.
Arcangeli S; Saracino B; Petrongari MG; Gomellini S; Marzi S; Landoni V; Gallucci M; Sperduti I; Arcangeli G
Radiother Oncol; 2007 Aug; 84(2):148-55. PubMed ID: 17692416
[TBL] [Abstract][Full Text] [Related]
11. Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer.
Zelefsky MJ; Levin EJ; Hunt M; Yamada Y; Shippy AM; Jackson A; Amols HI
Int J Radiat Oncol Biol Phys; 2008 Mar; 70(4):1124-9. PubMed ID: 18313526
[TBL] [Abstract][Full Text] [Related]
12. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime.
Martinez AA; Demanes DJ; Galalae R; Vargas C; Bertermann H; Rodriguez R; Gustafson G; Altieri G; Gonzalez J
Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1322-31. PubMed ID: 16029788
[TBL] [Abstract][Full Text] [Related]
13. Phase II dose escalation study of image-guided adaptive radiotherapy for prostate cancer: use of dose-volume constraints to achieve rectal isotoxicity.
Vargas C; Yan D; Kestin LL; Krauss D; Lockman DM; Brabbins DS; Martinez AA
Int J Radiat Oncol Biol Phys; 2005 Sep; 63(1):141-9. PubMed ID: 16111582
[TBL] [Abstract][Full Text] [Related]
14. Intensity-modulated radiation therapy for prostate cancer: late morbidity and results on biochemical control.
De Meerleer GO; Fonteyne VH; Vakaet L; Villeirs GM; Denoyette L; Verbaeys A; Lummen N; De Neve WJ
Radiother Oncol; 2007 Feb; 82(2):160-6. PubMed ID: 17222931
[TBL] [Abstract][Full Text] [Related]
15. Analysis of biochemical control and prognostic factors in patients treated with either low-dose three-dimensional conformal radiation therapy or high-dose intensity-modulated radiotherapy for localized prostate cancer.
Vora SA; Wong WW; Schild SE; Ezzell GA; Halyard MY
Int J Radiat Oncol Biol Phys; 2007 Jul; 68(4):1053-8. PubMed ID: 17398023
[TBL] [Abstract][Full Text] [Related]
16. Long-term results of conformal radiotherapy for prostate cancer: impact of dose escalation on biochemical tumor control and distant metastases-free survival outcomes.
Zelefsky MJ; Yamada Y; Fuks Z; Zhang Z; Hunt M; Cahlon O; Park J; Shippy A
Int J Radiat Oncol Biol Phys; 2008 Jul; 71(4):1028-33. PubMed ID: 18280056
[TBL] [Abstract][Full Text] [Related]
17. Five-year outcome of intraoperative conformal permanent I-125 interstitial implantation for patients with clinically localized prostate cancer.
Zelefsky MJ; Yamada Y; Cohen GN; Shippy A; Chan H; Fridman D; Zaider M
Int J Radiat Oncol Biol Phys; 2007 Jan; 67(1):65-70. PubMed ID: 17189063
[TBL] [Abstract][Full Text] [Related]
18. A dose-escalation trial with the adaptive radiotherapy process as a delivery system in localized prostate cancer: analysis of chronic toxicity.
Brabbins D; Martinez A; Yan D; Lockman D; Wallace M; Gustafson G; Chen P; Vicini F; Wong J
Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):400-8. PubMed ID: 15667959
[TBL] [Abstract][Full Text] [Related]
19. Biochemical (prostate-specific antigen) relapse-free survival and toxicity after 125I low-dose-rate prostate brachytherapy.
Khaksar SJ; Laing RW; Henderson A; Sooriakumaran P; Lovell D; Langley SE
BJU Int; 2006 Dec; 98(6):1210-5. PubMed ID: 17034501
[TBL] [Abstract][Full Text] [Related]
20. Hypofractionated boost to the dominant tumor region with intensity modulated stereotactic radiotherapy for prostate cancer: a sequential dose escalation pilot study.
Miralbell R; Mollà M; Rouzaud M; Hidalgo A; Toscas JI; Lozano J; Sanz S; Ares C; Jorcano S; Linero D; Escudé L
Int J Radiat Oncol Biol Phys; 2010 Sep; 78(1):50-7. PubMed ID: 19910135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]